Literature DB >> 18676737

Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression.

Emily C Brantley1, L Burton Nabors, G Yancey Gillespie, Youn-Hee Choi, Cheryl Ann Palmer, Keith Harrison, Kevin Roarty, Etty N Benveniste.   

Abstract

PURPOSE: STATs activate transcription in response to numerous cytokines, controlling proliferation, gene expression, and apoptosis. Aberrant activation of STAT proteins, particularly STAT-3, is implicated in the pathogenesis of many cancers, including GBM, by promoting cell cycle progression, stimulating angiogenesis, and impairing tumor immune surveillance. Little is known about the endogenous STAT inhibitors, the PIAS proteins, in human malignancies. The objective of this study was to examine the expression of STAT-3 and its negative regulator, PIAS3, in human tissue samples from control and GBM brains. EXPERIMENTAL
DESIGN: Control and GBM human tissues were analyzed by immunoblotting and immunohistochemistry to determine the activation status of STAT-3 and expression of the PIAS3 protein. The functional consequence of PIAS3 inhibition by small interfering RNA or PIAS3 overexpression in GBM cells was determined by examining cell proliferation, STAT-3 transcriptional activity, and STAT-3 target gene expression. This was accomplished using [(3)H]TdR incorporation, STAT-3 dominant-negative constructs, reverse transcription-PCR, and immunoblotting. RESULTS AND
CONCLUSIONS: STAT-3 activation, as assessed by tyrosine and serine phosphorylation, was elevated in GBM tissue compared with control tissue. Interestingly, we observed expression of PIAS3 in control tissue, whereas PIAS3 protein expression in GBM tissue was greatly reduced. Inhibition of PIAS3 resulted in enhanced glioblastoma cellular proliferation. Conversely, PIAS3 overexpression inhibited STAT-3 transcriptional activity, expression of STAT-3-regulated genes, and cell proliferation. We propose that the loss of PIAS3 in GBM contributes to enhanced STAT-3 transcriptional activity and subsequent cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18676737      PMCID: PMC3886729          DOI: 10.1158/1078-0432.CCR-08-0618

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  49 in total

1.  Stat3 as an oncogene.

Authors:  J F Bromberg; M H Wrzeszczynska; G Devgan; Y Zhao; R G Pestell; C Albanese; J E Darnell
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

2.  Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.

Authors:  Z Wen; Z Zhong; J E Darnell
Journal:  Cell       Date:  1995-07-28       Impact factor: 41.582

3.  Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells.

Authors:  M W MacCumber; C A Ross; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

Review 4.  Epidemiology and etiology of gliomas.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2005-02-01       Impact factor: 17.088

5.  Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1.

Authors:  Sébastien Loeffler; Bérengère Fayard; Joachim Weis; Jakob Weissenberger
Journal:  Int J Cancer       Date:  2005-06-10       Impact factor: 7.396

6.  A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells.

Authors:  K Nakajima; Y Yamanaka; K Nakae; H Kojima; M Ichiba; N Kiuchi; T Kitaoka; T Fukada; M Hibi; T Hirano
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

7.  Expression of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic response to IFN-alpha.

Authors:  Kazuto Takeuchi; Ikuya Sakai; Hirosi Narumi; Masaki Yasukawa; Kensuke Kojima; Yoko Minamoto; Tomoaki Fujisaki; Kazushi Tanimoto; Masamichi Hara; Akihiko Numata; Hisashi Gondo; Masuhiro Takahashi; Nobuharu Fujii; Kozo Masuda; Shigeru Fujita
Journal:  Leuk Res       Date:  2005-02       Impact factor: 3.156

Review 8.  Altered molecular pathways in gliomas: an overview of clinically relevant issues.

Authors:  Ravi D Rao; C David James
Journal:  Semin Oncol       Date:  2004-10       Impact factor: 4.929

9.  Differential hypermethylation of SOCS genes in ovarian and breast carcinomas.

Authors:  Kate D Sutherland; Geoffrey J Lindeman; David Y H Choong; Sergio Wittlin; Luci Brentzell; Wayne Phillips; Ian G Campbell; Jane E Visvader
Journal:  Oncogene       Date:  2004-10-07       Impact factor: 9.867

10.  Intercellular adhesion molecule-1 gene expression by glial cells. Differential mechanisms of inhibition by IL-10 and IL-6.

Authors:  P Shrikant; E Weber; T Jilling; E N Benveniste
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

View more
  81 in total

Review 1.  The impact of the Cancer Genome Atlas on lung cancer.

Authors:  Jeremy T-H Chang; Yee Ming Lee; R Stephanie Huang
Journal:  Transl Res       Date:  2015-08-10       Impact factor: 7.012

2.  STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.

Authors:  Vassiliki Kotoula; Sofia Lambaki; Despina Televantou; Anna Kalogera-Fountzila; Angelos Nikolaou; Konstantinos Markou; Despina Misailidou; Konstantinos N Syrigos; George Fountzilas
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

3.  Protein inhibitor of activated STAT3 expression in lung cancer.

Authors:  Amy Kluge; Snehal Dabir; Ilse Vlassenbroeck; Rosana Eisenberg; Afshin Dowlati
Journal:  Mol Oncol       Date:  2011-03-30       Impact factor: 6.603

4.  Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells.

Authors:  Braden C McFarland; G Kenneth Gray; Susan E Nozell; Suk W Hong; Etty N Benveniste
Journal:  Mol Cancer Res       Date:  2013-02-05       Impact factor: 5.852

Review 5.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

6.  SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage.

Authors:  Seong Won Lee; Moon Hee Lee; Jong Ho Park; Sung Hwan Kang; Hee Min Yoo; Seung Hyun Ka; Young Mi Oh; Young Joo Jeon; Chin Ha Chung
Journal:  EMBO J       Date:  2012-10-23       Impact factor: 11.598

Review 7.  Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma.

Authors:  Nathan B Roberts; Aniket S Wadajkar; Jeffrey A Winkles; Eduardo Davila; Anthony J Kim; Graeme F Woodworth
Journal:  Oncoimmunology       Date:  2016-08-19       Impact factor: 8.110

Review 8.  Epigenetics of neurological cancers.

Authors:  Shaun D Fouse; Joseph F Costello
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

9.  The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent.

Authors:  Snehal Dabir; Amy Kluge; Afshin Dowlati
Journal:  Mol Cancer Res       Date:  2009-11-10       Impact factor: 5.852

10.  Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway.

Authors:  Jun Wei; Jason Barr; Ling-Yuan Kong; Yongtao Wang; Adam Wu; Amit K Sharma; Joy Gumin; Verlene Henry; Howard Colman; Waldemar Priebe; Raymond Sawaya; Frederick F Lang; Amy B Heimberger
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.